SouthBayBio

Parkin (E3 Ligase) (human) (rec.) (His)

CHF 0.00
In stock
SBB-CE0055-C05050 µgINQ
More Information
Product Details
Synonyms PARK2; E3 Ubiquitin-protein Ligase Parkin; Parkin RBR E3 Ubiquitin-protein Ligase; Parkinson Juvenile Disease Protein 2; Parkinson Disease Protein 2; PRKN
Product Type Protein
Properties
Source/Host Sf9 cells
Sequence

Human Parkin (Accession Nr. O60260) is fused at the N-terminus to a His-tag.

Crossreactivity Human
Application

Typical working concentration range is from 1-5µM.

MW ~52kDa
Purity ≥95% (SDS-PAGE)
Concentration Lot dependent.
Accession Number O60260
Formulation Liquid. In 50mM Tris-HCl pH 8.0, 200mM sodium chloride, 10% glycerol, 5mM TCEP.
Other Product Data

Click here for a Typical Lot-specific Product Datasheet from the Original Manufacturer
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by South Bay Bio.
Shipping and Handling
Shipping DRY ICE
Short Term Storage -80°C
Long Term Storage -80°C
Handling Advice Aliquot to avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -80°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Parkin (Parkinson juvenile disease protein 2) is a ~52kDa E3 Ligase enzyme protein, encoded by the PARK2 gene. It plays an important role in the ubiquitin-proteasome system and acts as a regulator of protein breakdown. Parkin is located in the cytoplasma until a sustained depolarization occurs after which it is translocated to the mitochondrial membrane and induces the degradation of various membrane proteins. Parkin mutation leads to the accumulation of missfolded, aggregated proteins and degenerated mitochondria. The role of these changes in the pathomechanism of neurodegenerative diseases is well-known. Parkin mutation is responsible for about 50% of familial cases and for 10 to 20% of youth cases. Present views are that the improper regulation of protein aggregation and a dysfunction of the ubiquitin-proteasome system may be the common pathway of sporadic and hereditary Parkinson’s disease. In vitro, Parkin can be activated by treatment with recombinant PINK1, or addition of low concentrations of pS65-phosphoubiquitin. Parkin has been reported to generate poly-Ubiquitin chains in K6, K11, K48, and K63 linkages both in vitro and in vivo.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.